For further information:
Investor Relations (Tel: +34 91 244 44 22)
Marta Campos Martínez mcampos@rovi.es

ROVI announces the marketing agreement of Mysimba® in Spain

Madrid, 1 of August 2016 – Laboratorios Farmacéuticos Rovi, S.A. (ROVI or the "Company" hereafter) today announced an agreement with Orexigen Therapeutics Ireland Ltd. (Orexigen), a biopharmaceutical company focused on the treatment of obesity, for rights to market Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Spain.

Under this marketing agreement, ROVI will have exclusive rights in the Spanish territory to distribute Mysimba®, a medicine approved by the European Medicines Agency for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obese), or ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension).

ROVI expects to begin marketing Mysimba® by year-end 2016 for an initial period of five years, renewable for an additional five year period, according to the terms of the Agreement.

Obesity and related comorbidities are a significant health problem in Spain, where approximately 53% of adults are overweight or obese, according to recent statistics from the National Health Institute.

Juan López-Belmonte Encina, Chief Executive Officer of ROVI, commented: "We are very excited to offer specialist physicians this new pharmacological alternative for treating obesity. Obesity is a modern disease which is becoming increasingly prevalent among

the adult population. This new partnership advances our long-term objective to improve patients' quality of life. In addition, we expect Mysimba to contribute to the Group's revenue in the next few years, strengthening our specialty pharmaceutical product portfolio."

"We are excited to work with ROVI to bring Mysimba to the Spanish market as a differentiated new treatment option to address the significant and growing problem of obesity in Spain," said Michael Narachi, CEO of Orexigen. "With this agreement, Orexigen's first in Western Europe, we are continuing to execute on the company's ex-U.S. commercial strategy to expand the availability of Contrave® and Mysimba for patients and physicians by establishing agreements that support the drug's commercialization in additional territories worldwide."

About Mysimba®

Mysimba is approved in the European Union for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus or dyslipidemia). In the United States, the drug is approved as Contrave (naltrexone HCl / bupropion HCl extended release).

The exact neurochemical effects of Mysimba / Contrave leading to weight loss are not fully understood. Mysimba / Contrave has two components: naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Nonclinical studies suggest that naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake: the hypothalamus (appetite regulatory center) and the mesolimbic dopamine circuit (reward system).

Four 56-week multicenter, double-blind, placebo-controlled Phase 3 clinical trials were conducted to evaluate the effect of Mysimba / Contrave in conjunction with lifestyle modification in 4,536 subjects randomized to Mysimba / Contrave or placebo. In these studies, the most common adverse reactions (>5 percent) seen in patients taking

Mysimba / Contrave included nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea.

The clinical trial program also included a double-blind, placebo-controlled cardiovascular outcomes trial known as the Light Study. The primary objective of this study was to evaluate the occurrence of major adverse cardiovascular events (MACE) in overweight and obese adults with cardiovascular risk factors receiving Contrave. A second study, designed to address post-approval requirements in both Europe and the United States, is planned in order to further evaluate cardiovascular outcomes.

About ROVI

ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI's portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin. ROVI's research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISM® technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction. Additional information about ROVI is available on the company's website: www.rovi.es

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen's first product, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and became the most prescribed branded obesity medication in the United States in June 2015. In Europe, the drug has been approved under the brand name Mysimba® (naltrexone HCl/ bupropion HCl prolonged release). Orexigen is undertaking a range of development and commercialization activities, both on its own and with strategic partners, to bring Contrave / Mysimba to patients around the world. Further information about Orexigen can be found at www.orexigen.com